New Biomarker Predicts Non-Lymphocytic Lesions in Central Diabetes Insipidus Patients
Researchers show that patients with central diabetes insipidus who lack anti-rabphilin-3A antibodies could be at risk of tumor development
Read MorePosted by Andy Lundin | Nov 8, 2023 | Diabetes & Metabolic Diseases |
Researchers show that patients with central diabetes insipidus who lack anti-rabphilin-3A antibodies could be at risk of tumor development
Read MorePosted by Andy Lundin | Nov 3, 2023 | Kidney Disease |
Investigators developed an automated health maintenance tool to prompt physicians to screen for chronic kidney disease in diabetes patients.
Read MorePosted by Andy Lundin | Oct 20, 2023 | Diagnostic Technologies |
WHO updated its Essential Diagnostics List, a register of in vitro diagnostics supporting countries to make national diagnostic choices.
Read MorePosted by Chris Wolski | Oct 9, 2023 | Molecular Diagnostics |
The September/October 2023 Tech Guide that appears in CLP features a wide-range of products from top laboratory providers.
Read MorePosted by Andy Lundin | Oct 4, 2023 | Diabetes & Metabolic Diseases |
Adding screening for type 2 diabetes in accident and emergency departments could uncover thousands of previously undiagnosed cases every year.
Read More